25
Participants
Start Date
March 1, 2021
Primary Completion Date
January 1, 2025
Study Completion Date
January 1, 2025
Guselkumab
All subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44
RECRUITING
UCSF Psoriasis and Skin Treatment Center, San Francisco
Collaborators (1)
Janssen Biotech, Inc.
INDUSTRY
University of California, San Francisco
OTHER